Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

The U.S. tariffs on China include a broad 10% levy on imported goods. China’s response was more targeted, with 15% tariffs on ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Valerio Therapeutics is ending all clinical trials, including an ongoing phase 1/2 study for its investigational “DNA decoy” ...

Jan. 31, the CDC's chief science officer sent an internal email that informed the agency’s division heads that all papers ...

Canadian CRO Innovaderm Research is looking to grow with new CEO Jeff Smith leading the way. | Canadian CRO Innovaderm Research is looking to grow with new CEO Jeff Smith leading the way. Smith is ...